Bibliografía del artículo
1. Schwartz AV, Sellmeyer DE, Ensrud KE et al. Older women with diabetes have an increased risk of fracture: a pro-spective study. J Clin Endocrinol Metab 86;29-31, 2001.
2. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fracture in postmenopausal women. Diabetes Care 24:1192-1197, 2001.
3. Liberman UA, Weiss SR, Broll J et al. Effect of treatment with oral alendronate on bone mineral density and fracture incidence in postmenopausal osteoporosis. N Engl J Med 333:1437-1443, 1995.
4. Black DM, Cummings SR, Karpf DB et al. Fracture intervention trial research group : Randomised trial of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541, 1996.
5. Karpf DB, Shapiro DR, Seeman E et al. For the alendronate osteoporosis treatment study groups prevention of nonvertebral fractures by alendronate: A meta-analysis. JAMA 277:1159-1164, 1997.
6. Ikeda T, Manabe H, Iwata K. Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus. Diabetes Metab 30:355-358, 2004.
7. Keegan THM, Sellmeyer DE, Schwartz AV, Kelsey JL, Bauer DC. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women. The Fracture Intervention Trial. Diabetes Care 27:1547-1553, 2004.
8. Hanson DA, Weis ME, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258, 1992.
9. Johnston CC, Hui SL, Longcope C. Bone mass and sex steroid concentrations in postmenopausal Caucasian diabetics. Metabolism 34:544-550, 1985.
10. Van Daele PLA, Stolk RP, Burger H et al. Bone density in non-insulin-dependent diabetes mellitus: the Rotterdam study. Ann Intern Med 122:409-414, 1995.
11. Isaia G, Bodrato L, Carlevatto V, Mussetta M, Salomono G, Molinatti GM. Osteoporosis in type I diabetes. Acta Diabetol Lat 24:305-310, 1987.
12. Haffner SM, Bauer RL. The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metabolism 6:735-738, 1993.
13. Rosen HN, Dresner-Pollak R, Moses AC et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 54:26-29, 1994.
14. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641-649, 1995.
15. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsay L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomised clinical trial. J Bone Mineral Res 13:1431-1438, 1998.
16. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700, 1994.
17. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reduction in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592, 2002.